Hyperoxaluria-induced tubular ischemia: the effects of verapamil on the antioxidant capacity of the affected kidneys.
To evaluate the potential protective effects of a calcium channel blocker (Verapamil) on the oxidative stress related changes with an emphasis on the antioxidant capacity of the kidneys an experimental study in rats was performed. A total of 44 rats have been included. Hyperoxaluria was induced in Group 1 by continuous administration of ethylene glycol (EG). Animals in Group 2 received Verapamil in addition to EG. Animals in Group 3 constituted the control group. In addition to the evaluation of tissue and serum levels of three scavenging enzymes, NO, MDA and T-AOC; the presence and degree of crystal formation in renal parenchyma were evaluated in all animals after 7 and 28 days. Our data demonstrated that in addition to the lower level of all three scavenging enzymes (SOD, CAT and GSH) particularly during late phase evaluation (4 weeks); the total antioxidant capacity (T-AOC) of these kidneys were also higher when compared with the animals receiving EG only. Tissue and serum levels of both NO and MDA indicated the preventive effect of Verapamil on the oxidative stress induced changes. Very limited or no crystallization in the kidneys treated with verapamil during early and late phase examination was observed when compared with considerable crystal formation in Group 2 animals. Verapamil treatment may preserve the oxidant capacity of the kidneys and subsequently limit the crystal deposition induced by hyperoxaluria. Verapamil could therefore be considered in the management of kidney stone formation particularly in cases with recurrent kidney stone disease.
Department of Urology, Dr. Lutfi KIRDAR Research and Training Hospital, Gömeç sok. Sabancı -2 Sitesi A1 Kat 4 Daire 24 Acıbadem, Kadıköy, Istanbul, Turkey.
Kemal
K
Sarica
Department of Urology, Dr. Lutfi KIRDAR Research and Training Hospital, Gömeç sok. Sabancı -2 Sitesi A1 Kat 4 Daire 24 Acıbadem, Kadıköy, Istanbul, Turkey.
Alper
A
Kafkasli
Department of Urology, Dr. Lutfi KIRDAR Research and Training Hospital, Gömeç sok. Sabancı -2 Sitesi A1 Kat 4 Daire 24 Acıbadem, Kadıköy, Istanbul, Turkey.
Fehmi
F
Narter
Department of Molecular Medicine, Institute for Experimental Medical Research, University of Istanbul, Istanbul, Turkey.
Oguz
O
Ozturk
Department of Urology, Dr. Lutfi KIRDAR Research and Training Hospital, Gömeç sok. Sabancı -2 Sitesi A1 Kat 4 Daire 24 Acıbadem, Kadıköy, Istanbul, Turkey.
Ozgur
O
Yazici
Department of Urology, Dr. Lutfi KIRDAR Research and Training Hospital, Gömeç sok. Sabancı -2 Sitesi A1 Kat 4 Daire 24 Acıbadem, Kadıköy, Istanbul, Turkey.
Bilal
B
Hamarat
Department of Urology, Dr. Lutfi KIRDAR Research and Training Hospital, Gömeç sok. Sabancı -2 Sitesi A1 Kat 4 Daire 24 Acıbadem, Kadıköy, Istanbul, Turkey. cahitsahin129@gmail.com.
Cahit
C
Sahin
Department of Urology, Dr. Lutfi KIRDAR Research and Training Hospital, Gömeç sok. Sabancı -2 Sitesi A1 Kat 4 Daire 24 Acıbadem, Kadıköy, Istanbul, Turkey.
Bilal
B
Eryildirim
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D006959:Hyperoxaluria / Q000150:complications* / Q000378:metabolism*; D007511:Ischemia / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism; D007684:Kidney Tubules / Q000098:blood supply*; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014700:Verapamil / Q000627:therapeutic use*
D000975:Antioxidants; D002121:Calcium Channel Blockers; D014700:Verapamil
Antioxidant; Crystal deposition; Hyperoxaluria; Verapamil